Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.20 +0.9%	$2.29	$0.95 ▼ $2.85	$19.75M	0.13	596,526 shs	93,694 shs
FNCH Finch Therapeutics Group	$13.48 +12.1%	$12.77	$10.15 ▼ $15.85	$21.65M	1.19	2,237 shs	15,888 shs
KTTA Pasithea Therapeutics	$0.72 +0.7%	$0.72	$0.65 ▼ $7.50	$5.34M	0.26	2.88 million shs	33,150 shs
PMN Promis Neurosciences	$0.54 -2.4%	$0.59	$0.38 ▼ $1.59	$17.52M	-0.04	2.79 million shs	334,222 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	+1.40%	-0.46%	-14.84%	+11.22%	-18.96%
FNCH Finch Therapeutics Group	+12.05%	+5.81%	+8.80%	+3.69%	+22.10%
KTTA Pasithea Therapeutics	+0.98%	+1.34%	-1.10%	-22.20%	-85.10%
PMN Promis Neurosciences	+4.59%	-12.86%	-33.04%	+8.71%	-55.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	3.173 of 5 stars	3.5	2.0	0.0	3.4	0.0	0.0	0.6
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	1.2416 of 5 stars	0.0	5.0	0.0	0.0	2.9	0.0	0.6
PMN Promis Neurosciences	3.1043 of 5 stars	3.5	5.0	0.0	0.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	354.55% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
KTTA Pasithea Therapeutics	0.00	N/A	N/A	N/A
PMN Promis Neurosciences	3.00	Buy	$4.33	708.61% Upside

Current Analyst Ratings Breakdown

Latest KTTA, PMN, FNCH, and AYTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81.66M	0.24	N/A	N/A	$4.64 per share	0.47
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.04 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.01) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
KTTA Pasithea Therapeutics	-$13.90M	-$7.55	N/A	∞	N/A	N/A	-88.60%	-81.10%	N/A
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	N/A

Latest KTTA, PMN, FNCH, and AYTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	KTTA Pasithea Therapeutics	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
FNCH Finch Therapeutics Group	N/A	3.87	3.87
KTTA Pasithea Therapeutics	N/A	4.97	3.84
PMN Promis Neurosciences	N/A	0.97	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
FNCH Finch Therapeutics Group	21.77%
KTTA Pasithea Therapeutics	23.92%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
FNCH Finch Therapeutics Group	44.90%
KTTA Pasithea Therapeutics	2.70%
PMN Promis Neurosciences	6.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
KTTA Pasithea Therapeutics	3	7.44 million	7.24 million	Not Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable

KTTA, PMN, FNCH, and AYTU Headlines

Recent News About These Companies

ProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last year

August 13, 2025 | msn.com

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

August 13, 2025 | globenewswire.com

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 28, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 22, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

HC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation

July 15, 2025 | msn.com

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025 | globenewswire.com

ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's Disease

May 13, 2025 | nasdaq.com

ProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | Benzinga

May 13, 2025 | benzinga.com

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025 | globenewswire.com

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

March 31, 2025 | markets.businessinsider.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | finanznachrichten.de

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

March 24, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 | globenewswire.com

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 | globenewswire.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

February 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, PMN, FNCH, and AYTU Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.20 +0.02 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$2.19 -0.01 (-0.45%)

As of 05:54 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Finch Therapeutics Group NASDAQ:FNCH

$13.48 +1.45 (+12.05%)

As of 08/21/2025 03:58 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Pasithea Therapeutics NASDAQ:KTTA

$0.72 +0.01 (+0.70%)

Closing price 03:54 PM Eastern

Extended Trading

$0.70 -0.02 (-3.08%)

As of 06:36 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Promis Neurosciences NASDAQ:PMN

$0.54 -0.01 (-2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 +0.00 (+0.39%)

As of 07:18 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time